The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

2-AAF     N-(9H-fluoren-2-yl)ethanamide

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of ACETYLAMINOFLUORENE


High impact information on ACETYLAMINOFLUORENE


Chemical compound and disease context of ACETYLAMINOFLUORENE


Biological context of ACETYLAMINOFLUORENE


Anatomical context of ACETYLAMINOFLUORENE


Associations of ACETYLAMINOFLUORENE with other chemical compounds




Analytical, diagnostic and therapeutic context of ACETYLAMINOFLUORENE


  1. Gangliosides of liver tumors induced by N-2-fluorenylacetamide. I. Ganglioside alterations in liver tumorigenesis and normal development. Merritt, W.D., Richardson, C.L., Keenan, T.W., Morré, D.J. J. Natl. Cancer Inst. (1978) [Pubmed]
  2. Kinetics of depression and recovery of murine hepatic cytochrome P-450 levels after treatment with the interferon inducer polyriboinosinic-polyribocytidylic acid. Crowe, D.O., Reiners, J.J., Nerland, D.E., Sonnenfeld, G. J. Natl. Cancer Inst. (1986) [Pubmed]
  3. Alkaline phosphatase activity in hyperplastic and neoplastic urinary bladder epithelium of mice fed 2-acetylaminofluorene. Highman, B., Frith, C.H., Littlefield, N.A. J. Natl. Cancer Inst. (1975) [Pubmed]
  4. Analysis of agreement among findings of pathologists in ED01 experiment. Amato, D.A., Lagakos, S.W. J. Natl. Cancer Inst. (1988) [Pubmed]
  5. Incidence of pulmonary metastases for various neoplasms in BALB/cStCrlfC3H/Nctr female fed N-2-fluorenylacetamide. Frith, C.H., Littlefield, N.A., Umholtz, R. J. Natl. Cancer Inst. (1981) [Pubmed]
  6. Requirement for the replication protein SSB in human DNA excision repair. Coverley, D., Kenny, M.K., Munn, M., Rupp, W.D., Lane, D.P., Wood, R.D. Nature (1991) [Pubmed]
  7. Chromosomal localization of a unique gene by non-autoradiographic in situ hybridization. Landegent, J.E., Jansen in de Wal, N., van Ommen, G.J., Baas, F., de Vijlder, J.J., van Duijn, P., Van der Ploeg, M. Nature (1985) [Pubmed]
  8. Bone marrow as a potential source of hepatic oval cells. Petersen, B.E., Bowen, W.C., Patrene, K.D., Mars, W.M., Sullivan, A.K., Murase, N., Boggs, S.S., Greenberger, J.S., Goff, J.P. Science (1999) [Pubmed]
  9. Cell proliferation in carcinogenesis. Cohen, S.M., Ellwein, L.B. Science (1990) [Pubmed]
  10. Reduction of intestinal carcinogen absorption by carcinogen-specific secretory immunity. Silbart, L.K., Keren, D.F. Science (1989) [Pubmed]
  11. Dose-dependent reduction of N-2-fluorenylacetamide-induced liver cancer and enhancement of bladder cancer in rats by butylated hydroxytoluene. Maeura, Y., Weisburger, J.H., Williams, G.M. Cancer Res. (1984) [Pubmed]
  12. Ultrastructural abnormalities in carcinogen-induced hepatocellular altered foci identified by resistance to iron accumulation. Hirota, N., Williams, G.M. Cancer Res. (1982) [Pubmed]
  13. Cell proliferation induced by triiodothyronine in rat liver is associated with nodule regression and reduction of hepatocellular carcinomas. Ledda-Columbano, G.M., Perra, A., Loi, R., Shinozuka, H., Columbano, A. Cancer Res. (2000) [Pubmed]
  14. Persistently increased expression of a 3-methylcholanthrene-inducible phenol uridine diphosphate-glucuronosyltransferase in rat hepatocyte nodules and hepatocellular carcinomas. Bock, K.W., Münzel, P.A., Röhrdanz, E., Schrenk, D., Eriksson, L.C. Cancer Res. (1990) [Pubmed]
  15. Effect of 4-acetylaminofluorene and other tumour promoters on hepatocellular growth and binucleation. Gerlyng, P., Grotmol, T., Seglen, P.O. Carcinogenesis (1994) [Pubmed]
  16. Early stages of N-2-fluorenylacetamide-induced hepatocarcinogenesis in male and female rats and effect of gonadectomy on liver neoplastic conversion and neoplastic development. Katayama, S., Ohmori, T., Maeura, Y., Croci, T., Williams, G.M. J. Natl. Cancer Inst. (1984) [Pubmed]
  17. Shift from polyploidizing to nonpolyploidizing growth in carcinogen-treated rat liver. Saeter, G., Schwarze, E., Seglen, O. J. Natl. Cancer Inst. (1988) [Pubmed]
  18. Quantitative kinetics of development of N-2-fluorenylacetamide-induced, altered (hyperplastic) hepatocellular foci resistant to iron accumulation and of their reversion or persistence following removal of carcinogen. Williams, G.M., Watanabe, K. J. Natl. Cancer Inst. (1978) [Pubmed]
  19. Factors influencing the binding of N-2-fluorenylacetamide to specific regions of the hepatic genome in vivo in rats. Schwartz, E.L., Braselton, W.E., Goodman, J.I. J. Natl. Cancer Inst. (1981) [Pubmed]
  20. Absorption and protein binding of N-2-fluorenylacetamide and its metabolites in the bladder of rabbit. Hopp, M.L., Matsumoto, M., Lee, C., Oyasu, R. J. Natl. Cancer Inst. (1977) [Pubmed]
  21. Matrical inclusions induced by clofibrate in hepatic microbodies of rats fed 2-acetylaminofluorene. Tsukada, H., Mochizuki, Y., Gotoh, M. J. Natl. Cancer Inst. (1975) [Pubmed]
  22. DNA content of liver cell nuclei of N-2-fluorenylacetamide-induced altered foci and neoplasms in rats and human hyperplastic foci. Mori, H., Tanaka, T., Sugie, S., Takahashi, M., Williams, G.M. J. Natl. Cancer Inst. (1982) [Pubmed]
  23. Purification and transplantation of hepatocytes from livers of carcinogen-treated rats. Miller, S.B., Pretlow, T.P., Scott, J.A., Pretlow, T.G. J. Natl. Cancer Inst. (1982) [Pubmed]
  24. Bone marrow-derived hepatic oval cells differentiate into hepatocytes in 2-acetylaminofluorene/partial hepatectomy-induced liver regeneration. Oh, S.H., Witek, R.P., Bae, S.H., Zheng, D., Jung, Y., Piscaglia, A.C., Petersen, B.E. Gastroenterology (2007) [Pubmed]
  25. Expression of fibronectin and laminin in the rat liver after partial hepatectomy, during carcinogenesis, and in transplantable hepatocellular carcinomas. Sell, S., Ruoslahti, E. J. Natl. Cancer Inst. (1982) [Pubmed]
  26. Induction of replicative DNA synthesis in quiescent human fibroblasts by DNA damaging agents. Cohn, S.M., Krawisz, B.R., Dresler, S.L., Lieberman, M.W. Proc. Natl. Acad. Sci. U.S.A. (1984) [Pubmed]
  27. Polkappa protects mammalian cells against the lethal and mutagenic effects of benzo[a]pyrene. Ogi, T., Shinkai, Y., Tanaka, K., Ohmori, H. Proc. Natl. Acad. Sci. U.S.A. (2002) [Pubmed]
  28. Early resistance to cell death and to onset of the mitochondrial permeability transition during hepatocarcinogenesis with 2-acetylaminofluorene. Klöhn, P.C., Soriano, M.E., Irwin, W., Penzo, D., Scorrano, L., Bitsch, A., Neumann, H.G., Bernardi, P. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  29. Decreased fidelity of DNA polymerase activity during N-2-fluorenylacetamide hepatocarcinogenesis. Chan, J.Y., Becker, F.F. Proc. Natl. Acad. Sci. U.S.A. (1979) [Pubmed]
  30. Treatment with 2-AAF blocks the small hepatocyte-like progenitor cell response in retrorsine-exposed rats. Best, D.H., Coleman, W.B. J. Hepatol. (2007) [Pubmed]
  31. Analysis of damage tolerance pathways in Saccharomyces cerevisiae: a requirement for Rev3 DNA polymerase in translesion synthesis. Baynton, K., Bresson-Roy, A., Fuchs, R.P. Mol. Cell. Biol. (1998) [Pubmed]
  32. Mutational inactivation of the xeroderma pigmentosum group C gene confers predisposition to 2-acetylaminofluorene-induced liver and lung cancer and to spontaneous testicular cancer in Trp53-/- mice. Cheo, D.L., Burns, D.K., Meira, L.B., Houle, J.F., Friedberg, E.C. Cancer Res. (1999) [Pubmed]
  33. Induction of cMrp/cMoat gene expression by cisplatin, 2-acetylaminofluorene, or cycloheximide in rat hepatocytes. Kauffmann, H.M., Keppler, D., Kartenbeck, J., Schrenk, D. Hepatology (1997) [Pubmed]
  34. Pleiotrophin/heparin-binding growth-associated molecule as a mitogen of rat hepatocytes and its role in regeneration and development of liver. Asahina, K., Sato, H., Yamasaki, C., Kataoka, M., Shiokawa, M., Katayama, S., Tateno, C., Yoshizato, K. Am. J. Pathol. (2002) [Pubmed]
  35. Differential regulation of mdr genes in response to 2-acetylaminofluorene treatment in cultured rat and human hepatocytes. Lecureur, V., Guillouzo, A., Fardel, O. Carcinogenesis (1996) [Pubmed]
  36. Electron microscopic visualization of N-acetoxy-N-2-acetylaminofluorene binding sites in ColE1 DNA by means of specific antibodies. de Murcia, G., Lang, M.C., Freund, A.M., Fuchs, R.P., Duane, M.P., Sage, E., Leng, M. Proc. Natl. Acad. Sci. U.S.A. (1979) [Pubmed]
  37. Novel hepatic progenitor cell surface markers in the adult rat liver. Yovchev, M.I., Grozdanov, P.N., Joseph, B., Gupta, S., Dabeva, M.D. Hepatology (2007) [Pubmed]
  38. Dexamethasone inhibits the proliferation of hepatocytes and oval cells but not bile duct cells in rat liver. Nagy, P., Kiss, A., Schnur, J., Thorgeirsson, S.S. Hepatology (1998) [Pubmed]
  39. Metabolism and binding of benzo(a)pyrene and 2-acetylaminofluorene by short-term organ cultures of human and rat bladder. Moore, B.P., Hicks, R.M., Knowles, M.A., Redgrave, S. Cancer Res. (1982) [Pubmed]
WikiGenes - Universities